AFAnna Forsberg

Anna Forsberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Forsberg has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serrated polyp detection rates beyond adenoma detection rate for postcolonoscopy colorectal cancer: findings from the SCREESCO trial

    by Masau Sekiguchi, Marcus Westerberg, Anna Andreasson, Soran R. Bozorg, Anna M. Forsberg

    The association between serrated polyp detection rates, including proximal serrated polyp detection rate (PSPDR), and postcolonoscopy colorectal cancer (PCCRC) remains unestablished. We investigated PCCRC incidence and characteristics, and explored associations of PSPDR and adenoma detection rate (ADR) with PCCRC in colonoscopy- and fecal immunochemical test (FIT)-based screening within the Screening of Swedish Colons (SCREESCO) trial. Data from participants who underwent colonoscopy in the colonoscopy and FIT arms were analyzed. PCCRC, defined as colorectal cancer (CRC) diagnosed >6 months after a colonoscopy that did not detect CRC, was identified through linkage with cancer registries. Associations between PSPDR and PCCRC incidence were assessed using Cox models. Of 9982 and 5875 individuals in the colonoscopy and FIT arms, PCCRC was identified in 20 and 17 individuals, with 3-year PCCRC rates of 5.9% (3/51) and 3.5% (4/115), respectively. Compared with screening-detected CRC, PCCRC more often involved right-sided location and advanced stage. The 5-year cumulative incidence of PCCRC was 0.16% (95%CI 0.10%–0.27%) and 0.06% (95%CI 0.02%–0.15%) when colonoscopies were performed by endoscopists with low vs. high PSPDR (<10% vs. ≥10%), respectively. Among endoscopists with high ADR, 5-year PCCRC incidence was 0.13% (95%CI 0.04%–0.32%) vs. 0.06% (95%CI 0.02%–0.16%) for those with low vs. high PSPDR, respectively. Within this group, PCCRC incidence over 8 years decreased as PSPDR increased (hazard ratio per percentage-point increase, 0.90; 95%CI 0.82–1.00; P = 0.04). Despite the limited number of PCCRC events, this study suggests that PSPDR provides complementary information beyond ADR for identifying colonoscopies with higher PCCRC incidence.


  • Open Access

    Histological characteristics of the lower esophagus among persons with and without GERD in a general population

    by Jennifer Drevin, Peter T. Schmidt, Nicholas J. Talley, Michael Vieth, Michael P. Jones, Bengt Wallner, Per M. Hellström, Anna Forsberg, Lars Agréus, Anna Andreasson

    Gastroesophageal reflux disease (GERD) is one of our most common global health problems [1,2]. Globally, the estimated age-standardized prevalence of GERD, defined as heartburn and/or regurgitation...

  • Open Access

    Colonoscopy quality indicators among nurse endoscopists and physicians in population-based colorectal cancer screening in Sweden

    by Anna M Forsberg, Jóhann P Hreinsson, Peter T Schmidt, Johannes Blom, Colonoscopy Research Sweden (CRS)

    Background In Sweden, a nationwide colorectal cancer (CRC) screening program for individuals aged 60–74 started in 2021; to meet the increasing demand for colonoscopy, nurse endoscopists may play a key role – provided they maintain high technical quality. This observational study aimed to evaluate the nurse endoscopists’ performance in the screening program, focusing on core quality indicators. Methods Data were extracted from the Swedish Quality Register for Colonoscopies and Colorectal Cancer Screening (SveReKKS), including all screening colonoscopies performed between 1 April 2019 and 31 August 2025. Key quality indicators – adenoma detection rate (ADR), cecal and ileal intubation rates, bowel preparation, sedation use, and complications – were compared between nurse and physician endoscopists using generalized linear mixed-effects models with a logit link. Results Of 27 978 colonoscopies, 42 % were performed by nurses. Nurses had a higher ADR (57 % vs. 46 %; odds ratio [OR] 1.55, 95 %CI 1.47–1.62), and 3.6 % of the nurses had an ADR < 25 %, compared with 11.2 % of the physicians. Nurses also had higher odds of ileal intubation (OR 1.2, 95 %CI 1.1–1.2) and longer withdrawal times. Conclusions Nurse endoscopists demonstrated high quality colonoscopy performance in CRC screening and represent a valuable resource to meet increasing service demands without compromising clinical standards.

  • Open Access

    Author Correction: Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial

    by Marcus Westerberg, Jonas F. Ludvigsson, Chris Metcalfe, Ulf Strömberg, Johannes Blom, Lars Engstrand, Mikael Hellström, Christian Löwbeer, Robert Steele, Lars Holmberg, et al.

  • Investigating aspirin and post-colonoscopy colorectal cancer and cancer-specific mortality risk: a Swedish Register Study 2007–2016

    by Anna Forsberg, Linnea Widman, Anna Andreasson

    Objective: Acetylsalicylic acid (ASA) has been linked to reduced incidence and mortality in colorectal cancer (CRC), although its sex-specific effects remain unclear. Post-colonoscopy colorectal cancer (PCCRC), is a CRC diagnosed after a colonoscopy negative for cancer. The aim of this study was to explore the sex-specific effects of ASA on cancer-specific mortality risk in in CRC in general and in PCCRC specifically. Methods: This retrospective register-based study analyzed the conditional CRC-specific survival in 22 270 Swedish patients who underwent colonoscopy, including 1647 PCCRCs. The analyses were stratified on sex. Results: ASA use was associated with lower CRC mortality in men but not in women, hazard ratio (HR) = 0.85, 95% confidence interval (CI): 0.72–0.99, P = 0.043 for men and HR = 1.13, 95% CI: 0.93–1.37, P = 0.230 for women. Notably, ASA use in women, but not in men, with PCCRC was linked to increased mortality risk; HR for interaction PCCRC × ASA in women = 1.60, 95% CI: 1.02–2.51, P = 0.040 and HR for interaction PCCRC × ASA in men = 0.81, 95% CI: 0.50–1.32, P = 0.41. Conclusion: These exploratory analyses suggest sex-specific differences in the effect of ASA on CRC outcomes, particularly in PCCRC. Further research is needed to elucidate underlying the mechanisms and optimize chemopreventive strategies.

  • Top Cited Papers
    Open Access

    Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial

    by Marcus Westerberg, Jonas F. Ludvigsson, Chris Metcalfe, Ulf Strömberg, Johannes Blom, Lars Engstrand, Mikael Hellström, Christian Löwbeer, Robert Steele, Lars Holmberg, et al.

    There is a need to quantify the benefits and harms of colorectal cancer (CRC) screening using primary colonoscopy or fecal immunochemical testing (FIT) compared with usual care with no screening. Guidelines recommend screening in individuals aged 50–75 years using colonoscopy or FIT, and many screening programs use one-sample biennial FIT. Here we compare incidence of diagnosed CRCs and gastrointestinal and cardiovascular events between screening and usual care during the diagnostic phase of the SCREESCO trial. A randomized block method (no masking) assigned 278,280 individuals aged 60 years to once-only colonoscopy, 2 rounds of two-stool FIT with a low cutoff (10 μg g −1 feces) or usual care (control group) in a ratio of 1:6 for colonoscopy versus control and 1:2 for FIT versus control. In the analysis, 31,113 individuals were in the primary colonoscopy arm and 60,267 were in the FIT arm, and there were 186,671 primary colonoscopy controls, of whom 120,521 were also controls for comparison with the FIT arm. After a median follow-up of 4.8 years, the incidence rate of CRC was 107.9 in the colonoscopy arm and 99.9 in controls per 100,000 person-years (incidence rate ratio (IRR): 1.08, 95% confidence interval (CI): 0.91–1.28) and 96.0 in the FIT arm and 103.9 in controls (IRR: 0.92, 95% CI: 0.81–1.05). Rates of stage I–II CRC were higher in the colonoscopy arm (IRR: 1.38, 95% CI: 1.09–1.74) and in the FIT arm (IRR: 1.19, 95% CI: 0.99–1.43) versus controls. Rates of cardiovascular and gastrointestinal events were slightly higher in the intervention arms during the first year and were subsequently more similar to controls. Our findings of an increase in CRC detection implies a benefit of screening while the increase in adverse events suggests some initial harm. ClinicalTrials.gov: NCT02078804 .


  • First-Round Fecal Immunochemical Test Concentration Predicts Colorectal Cancer and Advanced Neoplasia in Second-Round Screening

    by Masau Sekiguchi, Marcus Westerberg, Christian Löwbeer, Johannes Blom, Anna Forsberg

    INTRODUCTION: Enhancing fecal immunochemical test (FIT)–based colorectal cancer (CRC) screening requires identifying additional predictive factors for colorectal neoplasia beyond current-round FIT concentration. We investigated whether first-round FIT concentration could predict colorectal neoplasia detection in the second screening round, using data from the randomized controlled trial Screening of Swedish Colons. METHODS: We conducted a cross-sectional analysis of Screening of Swedish Colons FIT-arm participants with negative 2-stool FIT (<10 μg Hb/g feces) in the first screening round, followed by a positive FIT (≥10 μg Hb/g feces) in the second round 2 years later with workup colonoscopy. We used binary regression models to assess risk factors for colorectal neoplasia, including CRC and advanced colorectal neoplasia (ACN), at colonoscopy, according to participants' characteristics and first-round and second-round FIT concentrations. RESULTS: In total, 1,991 individuals were included, with median FIT concentrations of 2.2 and 21.8 μg Hb/g feces in the first and second rounds, respectively. Higher first-round FIT concentration was associated with increased risks of CRC and ACN in the second round. Compared with those with first-round FIT concentrations of 0.0–1.9 μg Hb/g feces, the risk ratios for ACN were 1.38 (95% confidence interval 1.07–1.80) for 2.0–5.9 and 1.85 (95% confidence interval 1.38–2.48) for 6.0–9.9 μg Hb/g feces. For fixed second-round FIT concentration, the absolute risk of ACN increased in accordance with higher first-round FIT concentration. DISCUSSION: Even an increase in low levels of FIT concentration is associated with future CRC and ACN detection. Combining first-round and second-round FIT results could enhance the efficacy of screening.

  • Open Access

    Variation in fecal hemoglobin concentrations: Cross-sectional analysis of a screening trial and a screening program in Sweden

    by Masau Sekiguchi, Christian Löwbeer, Robert Steele, Johannes Blom, Anna Forsberg, Marcus Westerberg

    Objectives: To assess variation in fecal hemoglobin concentration according to year and season of fecal immunochemical test screening in Sweden, the detection rate of advanced neoplasia, and factors that could influence fecal immunochemical test positivity including sex, age, comorbidity, and laboratory testing quality. Methods: We performed a cross-sectional analysis of participants in the fecal immunochemical test arm of the randomized controlled trial SCREESCO between March 2014 and December 2019 and of participants in the screening program of Stockholm–Gotland, Sweden, who underwent a one-sample fecal immunochemical test between October 2015 and October 2024. Results: A total of 33,232 individuals from SCREESCO and 315,664 individuals from the Stockholm–Gotland screening program were included. Fecal immunochemical test hemoglobin concentrations were generally higher in the winter but this varied over calendar years. In SCREESCO, the median fecal immunochemical test concentration was 0.0 μg hemoglobin/g feces in December 2015, 1.0 μg hemoglobin/g feces in June and 5.0 μg hemoglobin/g feces in December 2016, and 0.0 μg hemoglobin/g feces in June 2017. This was paralleled by a similar variation in the Stockholm–Gotland screening program. In months with higher fecal immunochemical test positivity in SCREESCO, there was a higher number of colonoscopies and a lower rate of advanced neoplasia detected. Male sex, higher age, and higher comorbidity were also associated with higher fecal immunochemical test positivity. Conclusions: The variation in the number of colonoscopies and detection rate of advanced neoplasia paralleled the seasonal variation in fecal immunochemical test and warrants further studies on seasonal variation of fecal immunochemical test to optimize fecal immunochemical test-based colorectal cancer screening.

  • Open Access

    Complications of colonoscopy surveillance of patients with Lynch syndrome – 33 years of follow up

    by Alexander Frank, Sophie Walton Bernstedt, Nigin Jamizadeh, Anna Forsberg, Charlotte Hedin, Johannes Blom, Ann-Sofie Backman

    Background and study aims: Lynch syndrome (LS) is a hereditary autosomal dominant condition, with an increased lifetime risk of developing malignancies including colorectal cancer (CRC). Current guidelines differ in recommended colonoscopy-surveillance intervals from 1 to 2 years. Although colonoscopy is considered a safe procedure, there are risks of severe adverse events (SAEs), such as perforation and bleeding, as well as adverse events (AEs), such as abdominal discomfort and post-colonoscopy gastrointestinal infections. Colonoscopy-related bleeding and perforation rates have been reported 0.17% and 0.11%, respectively. However, there are insufficient data regarding complications of colonoscopy-surveillance for LS patients. This study aims to investigate the risk of AEs among LS patients during colonoscopy in the Stockholm region. Patients and methods: This retrospective cohort study includes 351 LS patients undergoing endoscopic surveillance at the Karolinska University Hospital, August 1989 – April 2021. Data from endoscopic surveillance colonoscopies were extracted from patients’ medical records. Results: Of 1873 endoscopies in 351 LS patients, 12 complications (AEs) were documented within 30 days (0.64%) and with a total of 3 bleedings (SAEs, 0.16%). No perforations were identified. Conclusion: Colonoscopy surveillance for LS patients shows a comparatively low risk of AEs per-examination. Colonoscopy complications per-patient, including both SAEs and AEs, show a significantly higher risk. Colonoscopy complications only including SAEs, show a comparatively low risk. Understanding the lifetime risk of surveillance-related colonoscopy complications is important when designing targeted surveillance programmes.